Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Bimekizumab 2mL vs 2x1mL Autoinjector
NCT05292131Phase 1Completed
- Sponsor
- UCB
- Start
- Mar 2022
- Primary completion
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of bimekizumab in plaque psoriasis, psoriatic arthritis (PsA), axial spondyloarthritis (axSpA) and 1 more (2 arms), sponsored by UCB. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity at Day 140, Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Concentration at Day 140 and 1 more. Started Mar 2022; status: completed.
02
Drugs
bimekizumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)axial spondyloarthritis (axSpA)hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05292131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05292131.